<DOC>
	<DOCNO>NCT00982020</DOCNO>
	<brief_summary>Open-label safety study oral olanzapine treatment adolescent , age 13 17 year , bipolar I disorder ( manic mixed episode ) schizophrenia .</brief_summary>
	<brief_title>Study Adolescents With Schizophrenia Bipolar Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Participants must diagnosis bipolar I disorder display acute manic mixed episode ( without psychotic feature ) diagnosis schizophrenia accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition Text Revision ( DSMIVTR ) confirm Kiddie Schedule Affective Disorders Schizophrenia School Aged ChildrenPresent Lifetime ( KSADSPL ) . Participants diagnosis schizophrenia must obtain Brief Psychiatric Rating Scale Children ( BPRSC ) total score &gt; 30 , minimum score 3 least one follow item screen randomization hallucination , delusion , peculiar fantasy . Participants diagnosis bipolar I disorder must Young Mania Rating Scale ( YMRS ) total score great equal 15 screen randomization . Has give assent ( applicable ) ; parent authorize legal representative give informed consent , reliable , level understanding sufficient permit participant perform test examination require protocol , understand nature study . History mental retardation , current comorbid autism , current comorbid Pervasive Developmental Disorder . Have DSMIVTR substance ( except nicotine caffeine ) dependence within past 30 day prior randomization . Been judge clinically suicidal risk . History allergic reaction hypersensitivity olanzapine . Receiving current pharmaceutical treatment weight management participate structure behavioral diet and/or exercise weight loss program . Other antipsychotic , mood stabilizer , anticonvulsant ( mood stabilization ) use primary study condition ( bipolar I disorder schizophrenia ) Have acute , serious , unstable medical condition Have illness death anticipate within 1 year intensive care unit hospitalization illness anticipate within 12 month ( 365 day ) . Have one seizure without clear resolve etiology . Baseline alanine aminotransferase ( ALT ) value great equal 2 time upper limit normal ( ULN ) perform laboratory aspartate aminotransferase ( AST ) value great equal 2 time ULN total bilirubin value great equal 1.5 time ULN screening . Have leukopenia history leukopenia without clear resolve etiology know history agranulocytosis ( absolute neutrophil count &lt; 500 cubic millimeter [ mm^3 ] , &lt; 0.5 GI/L , &lt; 0.5 10E^3/microliters [ Î¼L ] ) participant 's lifetime . Prolactin level &gt; 200 nanogram per milliliter ( ng/mL ) [ &gt; 200 microgram per liter ( ug/L ) , &gt; 4228 milliInternational unit per liter ( mIU/L ) ] screen . Have QTc ( Bazett 's ) &gt; 450 millisecond ( male ) &gt; 460 millisecond ( female ) screen . Previously randomize study and/or participate clinical trial another investigational drug , include olanzapine , within 1 month ( 30 day ) prior screen . Currently prescribe olanzapine great equal 5 day within 1 month ( 30 day ) prior screen . Are investigator site personnel directly affiliate study and/or immediate family OR employ representative Lilly . Pregnant nursing . Have receive treatment within last 30 day investigational new drug receive regulatory approval indication time study entry . Treatment clozapine within 14 day prior randomization . Participants use olanzapine ( , oral olanzapine , intramuscular [ IM ] olanzapine , olanzapine orally disintegrate tablet ) treatment withdrawn due clinically significant and/or intolerable adverse effect , exhibit lack efficacy/response treatment olanzapine include treatment resistance .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>safety</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>bipolar I ( manic mixed )</keyword>
	<keyword>adolescent</keyword>
	<keyword>weight management</keyword>
</DOC>